8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Apr 7, 2026·SEC
Material company update
Mar 17, 2026·SEC
Bluejay Diagnostics, Inc.(BJDX)Earnings, Financials & Key Ratios
BJDX•NASDAQ
$1.45
Price updated Jul 7, 2026
AboutBluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. In addition, it develops biomarkers for detection of other diseases such as hsTNT/I for myocardial injury and NT-proBNP for cardiac heart failure. It has a license and supply agreement with Toray Industries, Inc. for making and distributing the protein detection chips. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.Show more
- Revenue$0
- EBITDA-$7M+2.7%
- Net Income-$7M+11.3%
- EPS (Diluted)-15.25+96.7%
- ROE-117.02%+34.6%
BJDX Price & Volume
Bluejay Diagnostics, Inc. (BJDX) stock price & volume — 10-year historical chart
Loading chart...
Pre-Revenue Status Drives Persistent Liquidity Risk
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity and dilution
Key Thesis Takeaways
- Bluejay Diagnostics remains in a high-risk, pre-revenue developmental phase, characterized by significant quarterly operating losses that consistently exceed $1.5 million.
- The company's reliance on external financing to fund clinical trials for the Symphony platform creates substantial dilution risk for shareholders as the cash balance has eroded to $3.7 million.
- Investors should monitor the firm's ability to achieve regulatory milestones, as the current financial trajectory appears unsustainable without immediate capital infusion.
Verdict Logic
the company's cash position of $3.7 million against consistent quarterly losses of approximately $1.9 million in 2026Q1 suggests an imminent need for dilutive financing to maintain operations.
BJDX Growth Metrics
Bluejay Diagnostics, Inc. (BJDX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM4.83%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM97.06%
Return on Capital
10 Years-3007.93%
5 Years-101.07%
3 Years-138.46%
Last Year-117.38%
BJDX Recent Earnings
Bluejay Diagnostics, Inc. (BJDX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (43%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$1.95
—
Rev
—
—
Q2 2026
Mar 6, 2026Metric
Actual
Est
EPS
$2.37
—
Rev
—
—
Q4 2025
Nov 7, 2025Metric
Actual
Est
EPS
$4.04
—
Rev
—
—
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$1.41
—
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $1.95 | — |
| Q2 2026 | Mar 6, 2026 | $2.37 | — |
| Q4 2025 | Nov 7, 2025 | $4.04 | — |
| Q3 2025 | Aug 7, 2025 | $1.41 | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Bluejay Diagnostics, Inc. (BJDX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.45 | $657.63K | -0.10 | — | — | -117.02% | — | |
| $17.00 | $1.16B | -1.02 | -1.89% | -45.57% | -56.31% | — | |
| $33.39 | $87.75M | -3.98 | 195.75% | -59.65% | -98.3% | — | |
| $4.88 | $236.01M | -21.22 | -8.66% | -7.76% | -162.38% | — | |
| $570.25 | $45.29B | 43.60 | 10.42% | 24.63% | 70.87% | — | |
| $4.32 | $310.89M | -4.60 | -38.1% | -61.93% | -15.09% | — |
Compare BJDX vs Peers
Bluejay Diagnostics, Inc. (BJDX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BJDX SEC Filings & Documents
Bluejay Diagnostics, Inc. (BJDX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when BJDX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BJDX Frequently Asked Questions
Bluejay Diagnostics, Inc. (BJDX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is BJDX profitable?
Bluejay Diagnostics, Inc. (BJDX) reported a net loss of $6.9M for fiscal year 2025.
Dividend & Returns
What is BJDX's return on equity?
Bluejay Diagnostics, Inc. (BJDX) has a return on equity (ROE) of -117.0%. Negative ROE indicates the company is unprofitable.
What is Bluejay Diagnostics, Inc.'s free cash flow?
Bluejay Diagnostics, Inc. (BJDX) had negative free cash flow of $6.7M in fiscal year 2025, likely due to heavy capital investments.